First, our study cohort was small because we recruited patients with both T2DM and osteoporosis who were not having insulin therapy so that we could employ HOMA-IR and HOMA-β as surrogate markers of insulin resistance and insulin secretion. This evidence concerns the gene INS and type 2 diabetes mellitus.